A randomised phase III study in advanced oesophageal carcinoma to compare dysphagia in patients treated with radiotherapy versus chemo-radiotherapy.

People with cancer of the oesophagus (gullet) often have trouble swallowing. Radiotherapy can help improve this problem. Using chemotherapy together with radiotherapy may work better but has more side effects. This trial will determine if it is better to use radiotherapy by itself or together with chemotherapy.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

NCI CTG (ES 2)

Final Accrual

220

Trial Chairperson

Dr Michael Penniment, Royal Adelaide Hospital, SA

Trial Contact

sonya.stephens@health.sa.gov.au

Clinical Trial Registration

Related Post

Tour de Cure grants for TROG Cancer Research trials
9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital